Gil Blum, an analyst from Needham, maintained the Buy rating on Autolus Therapeutics (AUTL – Research Report). The associated price target remains the same with $10.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Gil Blum’s rating is based on several factors that highlight the potential of Autolus Therapeutics. During a recent conference, the company’s CEO, Christian Itin, emphasized the strategic focus on maintaining efficient transportation of patient cells between the US and the UK, which is crucial for their CAR-T therapies. This operational efficiency is vital for the company’s success and is not expected to be hindered by current regulatory changes or tariffs, as pharmaceuticals and blood-derived products remain exempt.
Additionally, the approval of Aucatzyl last year has positioned Autolus favorably in the market, suggesting a strong regulatory pathway for their products. These elements, combined with the company’s proactive management approach, underpin the Buy rating, as they indicate a promising outlook for Autolus Therapeutics in the biopharmaceutical sector.
In another report released on April 1, Truist Financial also reiterated a Buy rating on the stock with a $10.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue